DESTINY-06
06 Dec 2022
DESTINY-Breast06
NCT04494425
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
AstraZeneca
Cancer Type | Breast |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 Years to 105 Years |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2020-07-24 |
Anticipated End Date | 2023-07-31 |
Hospital | GenesisCare St Andrew's |
---|---|
Clinical Trial Coordinator | Kimberley Ruxton |
Kimberley.Ruxton@genesiscare.com | |
Phone | - |
Principal Investigator | Dr Nicholas Murray |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs